ANGION BIOMEDICA CORP. is a biopharmaceutical company based in Uniondale, New York. Their work involves discovering and developing novel therapeutic agents for acute and chronic organ injuries with an initial focus on nephrology. Angion’s therapeutic programs modulate the natural protective, reparative, and regenerative pathways of the body in both orphan diseases and larger clinical indications. The Company’s pre-clinical and clinical portfolio targets areas of high unmet need across a spectrum of therapeutic indications, including acute kidney injury and chronic kidney disease.
AviaraDx Inc., a leader in molecular cancer profiling, is focused on developing and commercializing molecular diagnostic technologies and high value assays for personalized medicine in cancer treatment. The company is targeting the oncology market with three first-in-class molecular cancer profiling technologies: Molecular Cancer Classification and Identification for Cancer of the Unknown Primary, Breast Cancer Assays such as HOXB13/IL 17BR, and Drug Response Profiling Assays. AviaraDx has licensed its technologies for specific clinical indications to reference laboratories in the United States and Europe.
In September 2008, AviaraDx was acquired by bioMerieux, which has re-named the company bioTheranostics. SDL Ventures was the lead investor in this successful divestiture.
ENTERA BIO, based in Wellesley Hills, Massachusetts, is focused on the development and commercialization of product candidates that leverage proprietary technology for the oral delivery of large molecule therapeutics. Recently, drug development has shifted towards the use of peptides, proteins and other large molecules for the treatment of various diseases. Oral drug delivery leads to higher patient and physician acceptance and provides significantly more flexibility, both in size of dose and number of doses per day, than injectable drugs. Entera’s proprietary technology facilitates the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation.
INNOVATE BIOPHARMACEUTICALS is focused on drug development for autoimmune and inflammatory diseases. Its lead product, Larazotide, a tight junction regulator, achieved excellent results in its Phase 2b trial against Celiac Disease. The company has fast track FDA approval for two Phase 3 trials starting in early 2018 and early 2019. Innovate has a second drug in the clinic, INN-108, which completed a successful Phase 1 trial in 2017 against Pediatric Ulcerative Colitis.
LEAF HEALTHCARE, INC., based in Pleasanton, California, develops and installs wireless patient monitoring solutions for health care providers seeking more efficient, cost effective ways to improve patient safety and clinical outcomes. The Leaf Patient Monitoring System wirelessly monitors a patient’s position and movement and uses that data to automate and document the management of prescribed mobility protocols for patients at risk of immobility related hospital acquired conditions such as pressure ulcers.
LEAF was acquired by Smith & Nephew in April 2019.
ONCTERNAL THERAPEUTICS is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medial need. They are committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types. As of the end of 2018, ONCTERNAL drug candidates were in Phase 1 clinical trials against chronic lymphocytic leukemia (CLL), advanced breast cancer, and Ewing sarcoma.
NEUROTROPE is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to develop targeted therapeutics for neurodegenerative diseases and developmental disorders. NEUROTROPE’s experience and passion for novel drug therapies have enabled it to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s Disease, Fragile X Syndrome and Niemann-Pick Type C.
The Company is currently in the middle of a Phase 2 confirmatory trial of Bryostatin-1 and advanced Alzheimer’s Disease.
RETROTOPE is a privately held company focused on the development of ways of controlling metabolic processes associated with the oxidative stress conditions. Areas of interest include age-related diseases. The company uses isotope effect to slow down damaging pathways. They have several discovery and development programs that involve major classes of biopolymers, with the major focus in neurological diseases such as Friedreich's ataxia.
RETROSENSE THERAPEUTICS, based in Ann Arbor, Michigan, is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). The RetroSense gene therapy technology has been demonstrated to confer light sensitivity to retinal nerve cells and restore functional vision in animal studies. The lead product candidate, RST-001, will be developed initially for RP with advanced dry-AMD as a follow-on indication.
In August 2016, RetroSense was purchased by Allergan Pharmaceuticals International, LTD and will continue to grow and develop its technology to restore vision.
selectION INC., based in San Diego, California, has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Its most advanced drug candidate is si-544, a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases. The Company is well positioned to expand its range of class leading ion channel blockers by targeting additional potassium, sodium, calcium and chloride channel, which will lead to other clinical applications in pain management and oncology.
SORRENTO THERAPEUTICS, INC., based in San Diego, California, is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases and bringing effective, non-opioid, pain medications to the market. SORRENTO’s approach to fighting cancer is made possible by its unique immune-oncology (“I-O”) portfolio, comprised of a wide array of innovative and synergistic assets such as a broad fully human antibody library (“G-MAB™”), clinical stage chimeric antigen receptor-T cells (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and an oncolytic virus (“Sephrehvir®”). The Company has generated fully human antibodies against many targets including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and CCR2, which are at various stages of development. It’s CAR-T programs include clinical stage CEA CAR-T and preclinical stage CD38 CAR-T. Cross-portfolio asset combination therapies are in preclinical stage evaluation for multiple myeloma, metastatic liver cancer, and other adult and pediatric cancers.
SORRENTO’s non-opioid pain management portfolio includes: ZTlido, a next generation lidocaine patch launched in October 2018; SP-102, a gel aimed at lumbar radicular pain and sciatica, currently in Phase 3; and RTX, a potent compound with many potential uses currently in a Phase 1B trial against osteoarthritis pain.